. Author manuscript; available in PMC: 2018 Jul 1.

Published in final edited form as: Mov Disord. 2017 May 13;32(7):955–971. doi: 10.1002/mds.27038

Table 1.

Levels of evidence for neuroimaging biomarkers in PSP

Level	Utility	PSP-RS	vPSP
1	Research tool	Group-level evidence that a biomarker is abnormal in PSP-RS	Group-level evidence that a biomarker is abnormal in vPSP
2	Supportive of clinical diagnosis	Individual-level data showing diagnostic value (high sensitivity + specificity) for PSP-RS	Individual-level data showing diagnostic value (high sensitivity + specificity) for vPSP
3	Supportive of early clinical diagnosis	Evidence for abnormalities before patients meet clinical criteria for PSP-RS	Evidence for abnormalities before patients meet clinical criteria for vPSP
4	Supportive of pathological diagnosis	Individual-level data showing diagnostic value for PSP pathology, regardless of syndrome
5	Definitive	Biomarker of actual pathology